Following is the list of attributes to be followed;
The purpose of the study is to develop an analytical method for the determination of Assay & Related substances in a new formulation product by HPLC using a UV-Visible detector.
This document will help analysts to develop robust Analytical methods for routine testing.
This guideline will provide information about analytical method development to be carried out as per ICH Guidelines.
- Physico-Chemical details of API:
Following items to be checked viz;
IUPAC name, Molecular formula, Chemical structure, Molecular weight, Solubility, Appearance, Melting Point, pH solubility, pKa, LogP, BCS Classification, Polymorphism, Isomerism, Density, Hygroscopicity, Impurities listed as per process either in DMF or official monograph
- Details of formulation product:
Following items to be checked viz;
Detailed Name, Molecular formula, Chemical structure, Molecular weight, Official monograph status in USP/BP/EP, Dosage form, Dosage strength, Maximum daily dose, Reporting and Identification thresholds, Reference listed drug / Innovator information, Solubility, pKa, impurities information, Information on potential metabolites.
- Literature review
- Impurities information from both API and finished product
- Route of synthesis of API to understand impurity profile
- Potential impurities with relevant information- process-related and degradant impurities
- Impurities structure, IUPAC name, molecular weight
- Chromatographic conditions:
- Selection of detector:
The detector can be selected based on the structure of the analyte and impurities, at times different detectors can be used.
- Wavelength selection:
This should be done based on the spectra of analytes or impurities.
- Buffer selection:
The buffer should be chosen based on the pH of solution/ pKa and the final pH of the buffer should be maintained at +/- 0.2 unit of the target pH, ensuring no distortion in peak shape during elution is found.
- Column selection:
A column can be selected based on the polarity of the Analyte and impurities.
- Mode of elution:
The initial assessment can be done using a different combination of gradient techniques to elute all possible impurities and then final fine-tuning should be done.
- Samples to be used for method development:
Initial 1 batch of formulation and API can be used for assessment, further, at least 3 different sets should be checked to get a consistent impurity profile.
- Sample extraction:
Appropriate diluent and technique to prepare the sample should be evaluated and further finalized.
Sample Assay after extraction should be in the range of 95% to 98% with an appropriate % of total impurities.
Test concentration and injection volume should be selected such that impurities LOQ are less than reporting threshold.
- Solution stability:
The solution stability of the standard and sample should be evaluated for at least 12 hours.
- Matrix interference study:
Relevant mobile phase blank, diluent blank, placebo blank, and interference from the syringe filter used for sample preparation should be evaluated.
- Finalization of method:
The method should be finalized after evaluating data for different robustness parameters such as the flow rate of the mobile phase, the temperature of the column, evaluating different make and series of columns, the pH of the mobile phase, the composition of the mobile phase, and system suitability parameters.
- Forced degradation:
Both API and the finished product should be treated for different stress conditions such as;
- Thermal: 105o C for 12 to 24 hours
- Water: Reflux for 12 to 24 hours
- Acid: Dilute acid treatment either immediately or after exposure for different time intervals
- Alkali: Dilute alkali treatment either immediately or after exposure for different time intervals
- Oxidation: Sample exposure to dilute oxidizing agent for different time intervals
- Photostability: Light exposure using 200 watts to achieve 1.2 million lux hour intensity
- Humidity: 60%RH for 7 days
After treatment of samples, they should be immediately analyzed, if required further dilution can be done to check Assay using a different method of short runtime than the related substances method and check for peak purity.
All data; Assay and impurity profiles should be tabulated based on RRT.
A mass balance should be calculated against a standard solution of API of the same concentration which is not treated.
Alternatively, samples can be evaluated via the LC-MS technique to gain information on major degradant impurities.
- Linearity and Accuracy studies:
Linearity studies are done to establish RRF (relative response factor) and Accuracy is done to ensure on spiking of impurities in related substance methods shows recovery in the range of at least 98%, additionally, the Assay method accuracy study is done to check recovery of drug from matrix.
- Comparison of Pharmacopeial and in-house developed methods:
Side by side comparison of both methods should be done and establish equivalency studies.
- System Suitability criteria:
Based on different studies carried out during method development and partial validation System suitability criteria such as theoretical plates, tailing factor, resolution, % RSD of standard, S/N ratio, and Capacity factor should be set based on data.
- Conclusion / Method development report:
- Document conclusions on stability indicating the performance of the method
- Based on robustness studies, clarify the sensitivity of the method
- Special precautions to be taken during using the method for routine testing
- Specific handling instructions of standards, samples, and chemicals
- Justification of specifications based on literature reference and tentative setting of specifications based on evaluation of Innovator product.
- Draft method of analysis, to be further verified by another analyst to ensure workability/ reproducibility of the method.
- All relevant chromatograms and documents can be attached for reference.
To know more about Impurities and Pharmaceutical Drug substances read our blogs or to buy them visit Our website https://veeprho.com/